Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Guizhou Medical Univ. SGK1 compound 7h: sourced facts only. name: "The results revealed that compound 7h exhibited stronger SGK1 inhibitory ability and superior in vitro antitumor activity, as well as better SGK family selectivity than H1." [PMID:42242016]; target: "The results revealed that compound 7h exhibited stronger SGK1 inhibitory ability and superior in vitro antitumor activity, as well as better SGK family selectivity than H1." [PMID:42242016]; developer: "School of Pharmacy, Guizhou University of Traditional Chinese Medicine, Guiyang 550025, China; State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Natural Products Research Center of Guizhou Province, Guizhou Medical University, Guiyang 550014, China." [PMID:42242016]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Guizhou Medical Univ. SGK1 compound 7h.